181641-00-9

Basic information

• Product Name: 2-(3,4-Difluorophenyl)-2-hydroxyacetonitrile
• Synonyms: 2-(3,4-Difluorophenyl)-2-hydroxyacetonitrile
• CAS NO: 181641-00-9
• Molecular Weight: 169.131
• Mol File: 181641-00-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(3,4-Difluorophenyl)-2-hydroxyacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-Difluorophenyl)-2-hydroxyacetonitrile(181641-00-9)
• EPA Substance Registry System: 2-(3,4-Difluorophenyl)-2-hydroxyacetonitrile(181641-00-9)

Safety Data

• Hazardous Substances Data: 181641-00-9(Hazardous Substances Data)

Upstream product

• 34036-07-2 3,4 difluorobenzaldehyde 

Downstream Products

• 10145-04-7 2-amino-1-(3,4-difluoro-phenyl)-ethanol 
• 20805-18-9 5-(3,4-difluoro-phenyl)-oxazolidin-2-one 
• 218451-28-6 (+)-3-(3-(4-cyano-4-(2,4-dichloro)phenylpiperidin-1-yl)propyl)aminocarbonyl-4-(3,4-difluorophenyl)-2-oxazolidinone 
• 218451-40-2 (+)-3-(3-(4-Aminocarbonyl-4-(4-chloro)phenylpiperidin-1-yl)-propyl)aminocarbonyl-4-(3,4-difluoro)phenyl-2-oxazolidinone 
• 218449-37-7 4-(3,4-difluorophenyl)-2-oxo-oxazolidine-3-carboxylic acid-4-nitro-phenyl ester 
• 218449-63-9 [2-(3,4-difluorophenyl)-2-hydroxy-ethyl]-carbamic acid-tert-butyl ester 
• 218449-35-5 [1-(3,4-difluorophenyl)-2-hydroxy-ethyl]-carbamic acid-tert-butyl ester 
• 225641-91-8 4-(3,4-difluorophenyl)-2-oxazolidinone 

Relevant articles and documents

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.